1. Home
  2. ATAI vs SMBK Comparison

ATAI vs SMBK Comparison

Compare ATAI & SMBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATAI
  • SMBK
  • Stock Information
  • Founded
  • ATAI 2018
  • SMBK N/A
  • Country
  • ATAI Germany
  • SMBK United States
  • Employees
  • ATAI N/A
  • SMBK N/A
  • Industry
  • ATAI Biotechnology: Pharmaceutical Preparations
  • SMBK Major Banks
  • Sector
  • ATAI Health Care
  • SMBK Finance
  • Exchange
  • ATAI Nasdaq
  • SMBK Nasdaq
  • Market Cap
  • ATAI 444.7M
  • SMBK 521.4M
  • IPO Year
  • ATAI 2021
  • SMBK N/A
  • Fundamental
  • Price
  • ATAI $2.48
  • SMBK $31.56
  • Analyst Decision
  • ATAI Strong Buy
  • SMBK Buy
  • Analyst Count
  • ATAI 3
  • SMBK 5
  • Target Price
  • ATAI $10.50
  • SMBK $34.40
  • AVG Volume (30 Days)
  • ATAI 2.7M
  • SMBK 60.4K
  • Earning Date
  • ATAI 08-12-2025
  • SMBK 07-21-2025
  • Dividend Yield
  • ATAI N/A
  • SMBK 1.01%
  • EPS Growth
  • ATAI N/A
  • SMBK 44.84
  • EPS
  • ATAI N/A
  • SMBK 2.26
  • Revenue
  • ATAI $1,863,000.00
  • SMBK $171,664,000.00
  • Revenue This Year
  • ATAI $554.22
  • SMBK $20.95
  • Revenue Next Year
  • ATAI N/A
  • SMBK $9.48
  • P/E Ratio
  • ATAI N/A
  • SMBK $13.99
  • Revenue Growth
  • ATAI 572.56
  • SMBK 16.34
  • 52 Week Low
  • ATAI $1.03
  • SMBK $21.56
  • 52 Week High
  • ATAI $2.64
  • SMBK $37.72
  • Technical
  • Relative Strength Index (RSI)
  • ATAI 66.50
  • SMBK 49.38
  • Support Level
  • ATAI $2.06
  • SMBK $30.95
  • Resistance Level
  • ATAI $2.55
  • SMBK $32.97
  • Average True Range (ATR)
  • ATAI 0.20
  • SMBK 0.67
  • MACD
  • ATAI -0.02
  • SMBK -0.13
  • Stochastic Oscillator
  • ATAI 72.41
  • SMBK 30.05

About ATAI ATAI Life Sciences N.V.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

About SMBK SmartFinancial Inc.

SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.

Share on Social Networks: